Lilly Mounjaro Zepbound highlights the worst entry points in pharma approvals and their proven impact on the market.
Medical device price cap is essential for affordable healthcare and transparency.
Pharma revenue growth is projected at 11-13% as exports expand beyond the US.
Compass psychedelic drug launch is paving the way for new treatments in mental health.
IV set price caps are under scrutiny by Maharashtra FDA for fairness in pricing.